

Ref. No: 679
From: Commercial
Date: 02/05/23
Subject: Usage of biologic and biosimilar products

REQUEST

It would be really helpful if you could provide the numbers of patients treated by the Rheumatology Department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

RESPONSE

Data: 1st February 2023 – 30th April 2023

Treatment	No. Patients Treated (Rheumatology)
Abatacept [Orencia]	55
Adalimumab [Humira]	41
Adalimumab Biosimilars	176
Apremilast [Otezla]	<5
Baricitinib [Olumiant]	74
Certolizumab [Cimzia]	15
Etanercept [Enbrel]	38

Etanercept Biosimilars	105
Filgotinib [Jyseleca]	18
Golimumab [Simponi]	34
Guselkumab [Tremfya]	0
Infliximab [Remicade]	<5
Infliximab Biosimilars	18
Ixekizumab [Taltz]	<5
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	13
Sarilumab [Kevzara]	0
Secukinumab [Cosentyx]	24
Tocilizumab [Ro Actemra]	34
Tofacitinib [Xeljanz]	36
Upadacitinib [Rinvoq]	<5
Ustekinumab [Stelara]	<5

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients cannot be identified.